secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-09-26T23:59:59+00:00
Accession:  0000950170-24-109644
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics submits NDA to FDA for paltusotine for acromegaly; Phase 3 data support submission
--------------------------------------------------------------------------------

- NDA supported by 18 clinical trials including two Phase 3 PATHFNDR studies; all primary and secondary endpoints met.
- FDA notification on NDA acceptance expected in December 2024.
- Paltusotine is first once-daily oral SST2 nonpeptide agonist in development for acromegaly.
- Drug also in Phase 2 for carcinoid syndrome associated with neuroendocrine tumors.
- CEO states submission is a key step toward delivering a new therapy for the acromegaly community.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024109644/0000950170-24-109644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024109644/crnx-20240926.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-109644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer